![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Susceptibility Screening to bNAbs Teropavimab (GS-5423)
and Zinlirvimab (GS-2872)
in ART-Suppressed Participants
|
|
|
CROI 2023 Feb 20-23
Lisa Selzer, Laurie A. VanderVeen, Aiyappa Parvangada, Ross Martin, Sean E. Collins, Megha Mehrotra, Christian Callebaut
Gilead Sciences, Inc., Foster City, CA
![0223231](../images/022423/022423-10/0223231.gif)
![0223232](../images/022423/022423-10/0223232.gif)
![0223233](../images/022423/022423-10/0223233.gif)
![0223234](../images/022423/022423-10/0223234.gif)
![0223235](../images/022423/022423-10/0223235.gif)
![0223236](../images/022423/022423-10/0223236.gif)
![0223237](../images/022423/022423-10/0223237.gif)
![0223238](../images/022423/022423-10/0223238.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|